Measurement of CNS atrophy

Multiple Sclerosis Therapeutics, Fourth Edition

Volumn , Issue , 2011, Pages 128-149

  Fisher, Elizabeth ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879775042     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139023986.014     Document Type: Chapter

References (178)

1. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125(8):1676-95.
2. Gyldensted C. Computer tomography of the cerebrum in multiple sclerosis. Neuroradiology 1976;12(1):33-42.
3. Sheldon JJ, Siddharthan R, Tobias J, Sheremata WA, Soila K, Viamonte M, Jr. MR imaging of multiple sclerosis: comparison with clinical and CT examinations in 74 patients. Am J Roentgenol 1985;145(5):957-64.
4. Janardhan V, Bakshi R. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch Neurol 2000;57(10):1485-91.
5. Simon JH, Jacobs LD, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999;53(1):139-48.
6. Turner B, Ramli N, Blumhardt LD, Jaspan T. Ventricular enlargement in multiple sclerosis: a comparison of three-dimensional and linear MRI estimates. Neuroradiology 2001;43(8):608-14.
7. Martola J, Bergstrom J, Fredrikson S, et al. A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images. Neuroradiology 2010;52(2):109-17.
8. Filippi M, Mastronardo G, Rocca MA, Pereira C, Comi G. Quantitative volumetric analysis of brain magnetic resonance imaging from patients with multiple sclerosis. J Neurol Sci 1998;158(2):148-53.
9. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119 (3):715-22.
10. Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998;121 (4):687-97.
11. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000;54(8):1689-91.
12. Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association between disability and biological markers in MS. Neurology 2001;57(7):1253-8.
13. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 2000;54(9):1734-41.
14. Dastidar P, Heinonen T, Lehtimaki T, et al. Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis. J Neurol Sci 1999;165(1):36-42.
15. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119 (6):2009-19.
16. Bedell BJ, Narayana PA. Automatic removal of extrameningeal tissues from MR images of human brain. J Magn Reson Imaging 1996;6(6):939-43.
17. Fisher E. Cothren RM. Tkach JA. Masaryk TJ. Cornhill JF. Knowledge-based 3D segmentation of MR images for quantitative MS lesion tracking. SPIE Med Imaging 1997;3034:19-25.
18. Goldszal AF, Davatzikos C, Pham DL, Yan MX, Bryan RN, Resnick SM. An image-processing system for qualitative and quantitative volumetric analysis of brain images. J Comput Assist Tomogr 1998;22(5):827-37.
19. Alfano B, Quarantelli M, Brunetti A, et al. Reproducibility of intracranial volume measurement by unsupervised multispectral brain segmentation. Magn Reson Med 1998;39(3):497-9.
20. Rovaris M, Inglese M, van Schijndel RA, et al. Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. J Neurol 2000;247(12):960-5.
21. Bermel RA, Sharma J, Tjoa CW, Puli SR, Bakshi R. A semiautomated measure of whole-brain atrophy in multiple sclerosis. J Neurol Sci 208;(1-2):57-65.
22. Chard DT, Parker GJ, Griffin CM, Thompson AJ, Miller DH. The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Res Imaging 2002;15(3):259-67.
23. Fox NC, Jenkins R, Leary SM, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI.[see comment]. Neurology 2000;54(4):807-12.
24. Smith SM, De SN, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25(3):466-75.
25. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 2000;11(6 pt 1):805-21.
26. Udupa JK, Wei L, Samarasekera S, Miki Y, van Buchem MA, Grossman RI. Multiple sclerosis lesion quantification using fuzzy-connectedness principles. IEEE Trans Med Imaging 1997;16(5):598-609.
27. Kikinis R, Guttmann CR, Metcalf D, et al. Quantitative follow-up of patients with multiple sclerosis using MRI: technical aspects. J Magn Reson Imaging 1999;9(4):519-30.
28. Horsfield MA, Rovaris M, Rocca MA, et al. Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. J Neurol Sci 2003;216(1):169-77.
29. Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004;62(8):1432-4.
30. Sharma J, Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Munschauer FE, III, Bakshi R. Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. Am J Neuroradiol. 2004;25(6):985-96.
31. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53(8):1698-704.
32. Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, Lim KO. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol 1994;51(9):874-87.
33. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17(1):479-89.
34. Sepulcre J, Sastre-Garriga J, Cercignani M, Ingle GT, Miller DH, Thompson AJ. Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. Arch Neurol 2006;63(8):1175-80.
35. Audoin B, Zaaraoui W, Reuter F, et al. Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81(6):690-5.
36. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79(11):1236-44.
37. Studholme C, Cardenas V, Schuff N, Rosen H, Miller B, Weiner M. Detecting spatially consistent structural differences in Alzheimer's and frontotemporal dementia using deformation morphometry MICCAI Proceedings 2001: 41-8.
38. Tao G, Datta S, He R, Nelson F, Wolinsky JS, Narayana PA. Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry. J Neurol Sci 2009;282(1-2):39-46.
39. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999;122(1):17-26.
40. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50(3):389-400.
41. Alfano B, Quarantelli M, Brunetti A, et al. Reproducibility of intracranial volume measurement by unsupervised multispectral brain segmentation.[see comment]. Magn Reson Med 1998;39(3):497-9.
42. Ge Y, Grossman RI, Udupa JK, Babb JS, Nyul LG, Kolson DL. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology 2001; 220(3):606-10.
43. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125(2):327-37.
44. Nakamura K, Fisher E. Segmentation of brain magnetic resonance images for measurement of gray matter atrophy in multiple sclerosis patients. Neuroimage 2009;44(3):769-76.
45. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23 (Suppl 1):S208-19.
46. Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 2004; 23(3):1168-75.
47. Sailer M, Fischl B, Salat D, et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003;126(8):1734-44.
48. Nakamura K, Fox R, Fisher E. CLADA: cortical longitudinal atrophy detection algorithm. Neuroimage 2011;54(1): 278-89.
49. Derakhshan M, Caramanos Z, Giacomini PS, et al. Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. Neuroimage 2010;52(4):1261-7.
50. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natal Acad Sci USA 2000; 97(20):11050-5.
51. Kim JS, Singh V, Lee JK, et al. Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification. Neuroimage 2005;27(1):210-21.
52. Charil A, Dagher A, Lerch JP, Zijdenbos AP, Worsley KJ, Evans AC. Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. Neuroimage 2007;34(2):509-17.
53. Simon JH, Schiffer RB, Rudick RA, Herndon RM. Quantitative determination of MS-induced corpus callosum atrophy in vivo using MR imaging. Am J Neuroradiol 1987; 8(4):599-604.
54. Edwards SG, Liu C, Blumhardt LD. Cognitive correlates of supratentorial atrophy on MRI in multiple sclerosis. Acta Neurol Scand 2001;104(4):214-23.
55. Bermel RA, Bakshi R, Tjoa C, Puli SR, Jacobs L. Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis. Arch Neurol 2002;59(2):275-80.
56. Meier DS, Fisher E. Atlas-based anatomic labeling in neurodegenerative disease via structure-driven atlas warping. J Neuroimaging 2005;15(1):16-26.
57. Evans A, Collins L, Holmes C, et al. A 3D probabilistic atlas of normal human neuroanatomy. Third International Conference on Functional Mapping of the Human Brain; 1997: 349.
58. Kikinis R, Shenton ME, Iosifescu DV, et al. Digital brain atlas for surgical planning, model-driven segmentation and teaching. IEEE Transa Visualization Comp Graphics 1996;2:232-41.
59. Ceccarelli A, Rocca MA, Pagani E, et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 2008;42(1):315-22.
60. Sicotte NL, Kern KC, Giesser BS, et al. Regional hippocampal atrophy in multiple sclerosis. Brain 2008;131(4):1134-41.
61. Sampat MP, Berger AM, Healy BC, et al. Regional white matter atrophy-based classification of multiple sclerosis in cross-sectional and longitudinal data. Am J Neuroradiol 2009;30(9):1731-9.
62. Audoin B, Davies G, Rashid W, Fisniku L, Thompson AJ, Miller DH. Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. Mult Scler 2007;13(4): 483-9.
63. Kidd D, horpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43(12):2632-7.
64. LosseffNA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119 (3):701-8.
65. Stevenson VL, Leary SM, LosseffNA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51(1):234-8.
66. Brex PA, Leary SM, O'Riordan JI, et al. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol, Neurosurg Psychiatry 2001;70(4):544-7.
67. Evangelou N, DeLuca GC, Owens T, Esiri MM. Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. Brain 2005;128(1):29-34.
68. Gilmore CP, DeLuca GC, Bo L, et al. Spinal cord atrophy in multiple sclerosis caused by white matter volume loss. Arch of Neurol 2005;62(12):1859-62.
69. Zivadinov R, Banas AC, Yella V, Abdelrahman N, Weinstock-Guttman B, Dwyer MG. Comparison of three different methods for measurement of cervical cord atrophy in multiple sclerosis. Am J Neuroradiol 2008;29(2):319-25.
70. Coulon O, Hickman SJ, Parker GJ, Barker GJ, Miller DH, Arridge SR. Quantification of spinal cord atrophy from magnetic resonance images via a B-spline active surface model. Magn Res Med 2002;47(6):1176-85.
71. Horsfield MA, Sala S, Neema M, et al. Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage 2010;50(2):446-55.
72. Song F, Huan Y, Yin H, et al. Normalized upper cervical spinal cord atrophy in multiple sclerosis. J Neuroimaging 2008;18(3):320-7.
73. Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004;62(8):1432-4.
74. Anderson VM, Bartlett JW, Fox NC, Fisniku L, Miller DH. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol 2007; 254(11):1588-94.
75. Altmann DR, Jasperse B, Barkhof F, et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 2009;72(7):595-601.
76. De Stebano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74(23):1868-76.
77. Barkhof F, Fisher E, Van Den Elskamp I, et al. The effect of temsirolimus on brain atrophy. Multi Scler 2009;15, S140. (Abstract)
78. Mehta LR, Schwid SR, Arnold DL, et al. Proof of concept studies for tissue-protective agents in multiple sclerosis. Mult Scler 2009;15(5): 542-6.
79. Healy B, Valsasina P, Filippi M, Bakshi R. Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80(11):1218-23.
80. Chard DT, Parker GJ, Griffin CM, Thompson AJ, Miller DH. The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J. Magn Reson Imaging 2002;15(3):259-67.
81. Sanfilipo MP, Benedict RH, Sharma J, Weinstock-Guttman B, Bakshi R. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 2005;26(4):1068-77.
82. Chard DT, Jackson JS, Miller DH, Wheeler-Kingshott CA. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging 2010;32(1):223-8.
83. Sampat MP, Healy BC, Meier DS, Dell'Oglio E, Liguori M, Guttmann CR. Disease modeling in multiple sclerosis: assessment and quantification of sources of variability in brain parenchymal fraction measurements. Neuroimage 2010;52(4):1367-73.
84. Tiberio M, Chard DT, Altmann DR, et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology 2005;64(6):1001-7.
85. Duning T, Kloska S, Steinstrater O, Kugel H, Heindel W, Knecht S. Dehydration confounds the assessment of brain atrophy. Neurology 2005;64(3):548-50.
86. Enzinger C, Ropele S, Smith S, et al. Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4. Ann Neurol 2004; 55(4):563-9.
87. Fox RJ, Fisher E, Tkach J, Lee JC, Cohen JA, Rudick RA. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Mult Scler 2005;11(2):140-5.
88. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338(5):278-85.
89. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.[see comment]. Arch Neurol 2001;58(1):65-70.
90. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127(5):1101-7.
91. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64(3):255-65.
92. Anderson VM, Fernando KT, Davies GR, et al. Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. J Neuroimaging 2007;17(1):61-8.
93. Di Filippo M, Anderson VM, Altmann DR, et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2010;81(2): 204-8.
94. Calabrese M, Atzori M, Bernardi V, et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007;254(9):1212-20.
95. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 2000;214(3):665-70.
96. Paolillo A, Pozzilli C, Gasperini C, et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. J Neurol Sci 2000;174(2):85-91.
97. Battaglini M, Giorgio A, Stromillo ML, et al. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. J Neurol Sci 2009;282(1-2):55-60.
98. Edwards SG, Gong QY, Liu C, et al. Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis. Brain 1999;122(2):291-301.
99. Chard DT, Griffin CM, Rashid W, et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Multi Scler 2004;10(4):387-91.
100. Lin X, Blumhardt LD, Constantinescu CS. The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. Acta Neurol Scand 2003;108(6):401-6.
101. Tedeschi G, Lavorgna L, Russo P, et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005;65(2):280-5.
102. Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002;59(10):1572-6.
103. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000;55(11):1714-8.
104. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000;123 (11):2256-63.
105. Stevenson VL, Miller DH, Rovaris M, et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 1999;52(4):839-45.
106. Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 2001;124(12):2540-9.
107. Rovaris M, Judica E, Sastre-Garriga J, et al. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler 2008;14(4):455-64.
108. Pagani E, Rocca MA, Gallo A, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. Am J Neuroradiol 2005;26(2):341-6.
109. Simon JH. From enhancing lesions to brain atrophy in relapsing MS. [Review]. J Neuroimmunol 1999;98(1):7-15.
110. LeistTP, GobbiniMI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001;58(1):57-60.
111. Luks TL, Goodkin DE, Nelson SJ, Majumdar S, Bacchetti P, Portnoy D, et al. A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis. Mult Scler 2000;6(5):332-7.
112. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001;124(9): 1803-12.
113. Lin X, Blumhardt LD. Inflammation and atrophy in multiple sclerosis: MRI associations with disease course. J Neurol Sci 2001;189(1-2):99-104.
114. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999;53(4):751-7.
115. Saindane AM, Ge Y, Udupa JK, Babb JS, Mannon LJ, Grossman RI. The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS. Neurology 2000;55(1):61-5.
116. Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 2000;6(6):365-72.
117. Inglese M, Mancardi GL, Pagani E, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol, Neurosurg Psychiatry 2004;75(4):643-4.
118. Jasperse B, Minneboo A, de G, et al. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. Arch Neurol 2007;64(2): 190-4.
119. Mesaros S, Rocca MA, Sormani MP, Charil A, Comi G, Filippi M. Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study. J Neurol 2008;255(9):1378-83.
120. Frank JA, Richert N, Bash C, et al. Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology 2004;62(5):719-25.
121. Paolillo A, Piattella MC, Pantano P, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004;251(4):432-9.
122. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59(9):1412-20.
123. Zivadinov R, Rudick RA, De MR, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57(7):1239-47.
124. Chard DT, Brex PA, Ciccarelli O, et al. The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol, NeurosurgPsychiatry 2003;74(11):1551-4.
125. Quarantelli M, Ciarmiello A, Morra VB, et al. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage 2003;18(2):360-6.
126. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64(3):247-54.
127. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003;60(7):1157-62.
128. Sastre-Garriga J, Ingle GT, Chard DT, et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 2005;128(6):1454-60.
129. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50(5):1282-8.
130. Kalkers NF, Bergers E, Castelijns JA, et al. Optimizing the association between disability and biological markers in MS. Neurology 2001;57(7):1253-8.
131. Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F. Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. Multi Scler 2002;8(5):410-4.
132. Furby J, Hayton T, Altmann D, et al. Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis. Mult Scler 2009;15(6):687-94.
133. Brochet B, Dousset V. Pathological correlates of magnetization transfer imaging abnormalities in animal models and humans with multiple sclerosis. Neurology 1999;53(Suppl 3):S12-17.
134. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56(3):407-15.
135. Rovaris M, Bozzali M, Rodegher M, Tortorella C, Comi G, Filippi M. Brain MRI correlates of magnetization transfer imaging metrics in patients with multiple sclerosis. J Neurol Sci 1999;166(1):58-63.
136. Traboulsee A, Dehmeshki J, Peters KR, et al. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler 2003;9(6):566-73.
137. De Stefano N, Iannucci G, Sormani MP, et al. MR correlates of cerebral atrophy in patients with multiple sclerosis. J Neurol 2002;249(8):1072-7.
138. Ge Y, Gonen O, Inglese M, Babb JS, Markowitz CE, Grossman RI. Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology 2004;62(4):624-7.
139. Rovaris M, Gallo A, Falini A, et al. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol 2005; 62(6):898-902.
140. Bermel RA, Puli SR, Rudick RA, et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005;62(9):1371-6.
141. Raz E, Cercignani M, Sbardella E, et al. Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Radiology 2010;257(2):448-54.
142. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997;42(3):379-82.
143. Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000;6(6):373-7.
144. Rudick RA, Lee JC, Nakamura K, Fisher E. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009;282(1-2):106-11.
145. Minneboo A, Jasperse B, Barkhof F, et al. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. J Neurol Neurosurg Psychiatry 2008;79(8):917-23.
146. Di FM, Anderson VM, Altmann DR, et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2010;81(2):204-8.
147. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001;56(10):1324-30.
148. Jasperse B, Vrenken H, Sanz-Arigita E, et al. Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. Neuroimage 2007;38(3):529-37.
149. Rao SM, Glatt S, Hammeke TA, et al. Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment. Arch Neurol 1985;42(7): 678-82.
150. Hohol MJ, Guttmann CR, Orav J, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997;54(8):1018-25.
151. Benedict RH, Carone DA, Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. [Review]. J Neuroimaging 2004; 14(3 Suppl): 36S-45S.
152. Lazeron RH, Boringa JB, Schouten M, et al. Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. Mult Scler 2005;11(5):524-31.
153. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004;62(4): 586-90.
154. Marrie RA, Fisher E, Miller DM, Lee JC, Rudick RA. Association of fatigue and brain atrophy in multiple sclerosis. J Neurol Sci 2005;228(2): 161-6.
155. Tedeschi G, Dinacci D, Lavorgna L, et al. Correlation between fatigue and brain atrophy and lesion load in multiple sclerosis patients independent of disability. J Neurol Sci 2007;263(1-2):15-19.
156. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol 2004;61(2):226-30.
157. Amato MP, Bartolozzi ML, Zipoli V, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 2004;63(1):89-93.
158. Amato MP, Portaccio E, Goretti B, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 2007;64(8):1157-61.
159. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009;66(9):1144-50.
160. Benedict RH, Zivadinov R, Carone DA, et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. Am J Neuroradiol 2005;26(7):1824-31.
161. Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol Neurosurg Psychiatry 2009;80(2):201-6.
162. Bonati U, Fisniku LK, Altmann DR, et al. Cervical cord and brain grey matter atrophy independently associate with long-term MS disability. J Neurol Neurosurg Psychiatry 2010;82 (4): 471-2.
163. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009;5(5):256-66.
164. Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.[see comment]. J Neurol, Neurosurg Psychiatry 2003;74(8):1090-4.
165. Wolinsky JS, Narayana PA, Johnson KP, Multiple Sclerosis Study Group and the MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Multi Scler 2001;7(1):33-41.
166. Jones CK, Riddehough A, Li DKB, et al. MRI cerebral atrophy in relapsing-remitting MS: results from the PRISMS trial. Neurology 2001;56[Suppl 3]: A379.
167. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53(8):1698-704.
168. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo- controlled trial of natalizumab in relapsing MS. Neurology 2007;68(17): 1390-401.
169. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000;123 (11): 2256-63.
170. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8(10): 889-97.
171. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359(17):1786-801.
172. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364(9444):1489-96.
173. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401.
174. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402-15.
175. Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 2010;74(13):1033-40.
176. Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010;9(7):681-8.
177. Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007;13(4):490-501.
178. Nakamura K, Rudick RA, Lee J-C, Foulds P, Fisher E. Effect of Intramuscular Interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis. Neurology 2010; 74(Suppl 2); A 407.